| Abstrakt: |
In the course of this research, complement activation and antiphospholipid antibody (aPL) levels were investigated in individuals suffering from lupus nephritis. In this study, a retrospective analysis was performed on individuals who had kidney biopsies that were positive for LN. For the purpose of determining the levels of anticardiolipin antibodies (aCLs) and anti-ß2-glycoprotein I (anti-ß2-GPI) antibodies belonging to the IgM, IgA, and IgG classes, thorough research was carried out. Concurrent with the kidney biopsy, information on clinical symptoms and pathology was also collected. Nearly half (45.8% to be exact) of the forty people with LN who participated in the study tested positive for antiphospholipid antibodies (aPLs). "Individuals who were diagnosed with LN and did not possess any antiphospholipid antibodies (aPLs) displayed elevated levels of glomerulus C1q, decreased levels of serum complement proteins C3 and C4, increased levels of hematuria, and higher scores on the SLEDAI (P<0.05). It was shown that there was an inverse association between the levels of C3 and C4 in the blood and the IgG-aCL (r=-0.31, P=0.007; r=-0.36, P=0.028). It was shown that there is a significant link between the levels of IgG-aCL and the deposits of glomerulus C4 (r=0.31, P=0.043)." This connection turned out to be essential. The findings presented here indicate that IgG-aCLs have the potential to exacerbate LN and activate complement pathways. [ABSTRACT FROM AUTHOR] |
